Skip to main content

IQVIA company profile

  • IQV · NYSE
  • Biotechnology
  • Life Sciences Tools & Services
  • S&P 500
$265.12−2.21%Close 13 Nov 2026 · Market value $43.51B

About IQVIA

IQVIA is a global provider of clinical research services, commercial insights and healthcare intelligence to life sciences and healthcare organizations. Its offerings span three reportable segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Products include cloud-based commercial and clinical applications, real-world evidence services, market information and reference databases, and clinical trial services such as site management, monitoring, and central laboratory support. Clients include biopharmaceutical, biotechnology, medical device and diagnostic companies, along with payers, government agencies, providers, and pharmacies. IQVIA employs approximately 93,000 people and operates in over 100 countries.

A summary of the business section of the company's latest annual report, filed 17 Feb 2026.

Company facts

TickerIQV · NYSE
SectorBiotechnology
IndustryLife Sciences Tools & Services
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK1478242
Latest annual report10-K, filed 17 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
John M. Leonard, M.D.Director15.4K · < 1%Grant or award, 23 Apr 2026
Berkshire James G.See Remarks—Disposition to the issuer, 2 Sep 2026
STAUB W RICHARDSee Remarks—Open-market sale, 3 Aug 2026
Patel BhavikSee Remarks—Open-market sale, 31 Jul 2026
Sherbet EricSee Remarks—Open-market sale, 29 Jul 2026
Cherofsky KeriannSee Remarks—Open-market sale, 29 Jul 2026
BOUSBIB ARISee Remarks · Director—Disposition to the issuer, 29 Jul 2026
GOGGINS COLLEEN ADirector—Grant or award, 23 Apr 2026
DANHAKL JOHN GDirector—Grant or award, 23 Apr 2026
Burt CarolDirector—Grant or award, 23 Apr 2026
Haas BerndSee Remarks—Shares withheld for tax, 13 Feb 2026
Fedock Michael J.See Remarks—Shares withheld for tax, 13 Feb 2026
Grenfell AlistairSee Remarks—Shares withheld for tax, 8 Feb 2026
Bruehlman Ronald ESee Remarks—Grant or award, 8 Feb 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

IQV in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.